Neovasc to Participate in 10th Annual SVB Leerink Global Healthcare Conference
Neovasc Inc. (NASDAQ: NVCN, TSX: NVCN) has announced its participation in the 10th Annual SVB Leerink Global Healthcare Conference from February 24 to 26, 2021. CEO Fred Colen will present on February 26, 2021, at 1:00 pm EST. Investors can access the live webcast through Neovasc's investor relations page. Neovasc is recognized for its innovative medical devices aimed at the cardiovascular market, including the Neovasc Reducer™ for refractory angina and the Tiara™ for mitral valve disease treatment, currently under clinical investigation.
- None.
- None.
VANCOUVER, Feb. 17, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Neovasc Inc. (NASDAQ, TSX: NVCN), today announced that company management will be participating in the 10th Annual SVB Leerink Global Healthcare Conference that is scheduled to take place from February 24 to 26, 2021. Fred Colen, Neovasc’s President and Chief Executive Officer, will present on Friday, February 26, 2021 at 1:00 pm EST.
A link to the live webcast of the presentation will be available online from the investor relations section of the Neovasc website at https://www.neovasc.com/investors/.
About Neovasc Inc.
Neovasc is a specialty medical device company that develops, manufactures and markets products for the rapidly growing cardiovascular marketplace. The Company is a leader in the development of minimally invasive transcatheter mitral valve replacement technologies, and minimally invasive devices for the treatment of refractory angina. Its products include the Neovasc Reducer™, for the treatment of refractory angina, which is not currently commercially available in the United States (2 U.S. patients have been treated under Compassionate Use) and has been commercially available in Europe since 2015, and Tiara™, for the transcatheter treatment of mitral valve disease, which is currently under clinical investigation in the United States, Canada, Israel and Europe. For more information, visit: www.neovasc.com.
Investors
Mike Cavanaugh
Westwicke/ICR
Phone: +1.646.877.9641
Mike.Cavanaugh@westwicke.com
Media
Sean Leous
Westwicke/ICR
Phone: +1.646.677.1839
Sean.Leous@icrinc.com
Forward-Looking Statement Disclaimer
Certain statements in this news release contain forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and applicable Canadian securities laws that may not be based on historical fact. When used herein, the words "expect", "anticipate", "estimate", "may", "will", "should", "intend," "believe", and similar expressions, are intended to identify forward-looking statements. Forward-looking statements may involve, but are not limited to the expansion of its product range and the growing cardiovascular marketplace. Forward-looking statements are based on estimates and assumptions made by the Company in light of its experience and its perception of historical trends, current conditions and expected future developments, as well as other factors that the Company believes are appropriate in the circumstances. Many factors could cause the Company's actual results, performance or achievements to differ materially from those expressed or implied by the forward-looking statements, including those described in the "Risk Factors" section of the Company's Annual Report on Form 20-F and in the Management's Discussion and Analysis for the three and nine months ended September 30, 2020 (copies of which may be obtained at www.sedar.com or www.sec.gov). These factors should be considered carefully, and readers should not place undue reliance on the Company's forward-looking statements. The Company has no intention and undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
FAQ
When is Neovasc's presentation at the SVB Leerink Global Healthcare Conference?
Where can I watch the Neovasc conference presentation?
What products does Neovasc specialize in?
Is the Neovasc Reducer™ available in the U.S.?
What is the focus of Neovasc's clinical investigations?
